Pulmonary arterial hypertension (PAH) – is a condition wherein increased pressure is created in pulmonary arteries owing to structural changes in blood vessel walls, unusual platelets collection and unsmooth muscle cell function. This often leads to right heart failure and, ultimately, death. According to health regulatory bodies such as Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), nearly 15 to 50 patients per million of the population are likely to be affected by pulmonary arterial hypertension. In a recently published outlook, factors such as the rarity of the disease and the complexity of diagnosing it will contribute to the extremely slow growth of global pulmonary arterial hypertension treatment market, which is expected to witness a sluggish CAGR of 2.5% between 2018 and 2028.
However, research experts along with medical practitioners are working on various drug formulations and combination therapies for effective treatment of pulmonary arterial hypertension and to increase survival rate among the patients and also to forestall the decline of pulmonary arterial hypertension market. Some recent treatment options- still in research phase include:
‘Fibrosis’ Controlling Cancer Protein Molecules
Fibrosis- or commonly called ‘scarring’ causes severe damage to pulmonary arteries affecting heart functions leading breathlessness. In a recent research at Brigham and Women’s Hospital, researchers identified that the cancer protein NEDD9 and its molecular mechanisms may prove to be a potential treatment for PAH patients. By establishing a correlation between proteins and its pathways- called medicine network- researchers found that a specific amino acid residue in NEDD9 cancer protein is expected to control fibrosis.
Naturally Occurring BH4 to Lower Lung Hypertension
Researchers at Imperial College London and Bar-Ilan University, Israel have found that naturally occurring tetrahydrobiopterin (BH4) contains properties that would be effective in treating lung hypertension and right heart failure. The researchers tested the functioning of BH4 on a rat model. Initially, the rats were injected with a chemical triggered pulmonary arterial hypertension and then with BH4- indicating reduced lung pressure. The first ‘controlled’ batch of patients administered BH4 orally- in the form of tablets, showed improved exercise capacity- often associated with low lung pressure.
Risk Prediction Tools
According to several studies, the average life expectancy of pulmonary arterial hypertension patient is approximately 3 years from symptom onset. Here, experts and medical practitioners have expressed the need to develop accurate risk prediction tools which will help in early diagnosis- leading to better treatment outcomes. Research shows survival rate among ‘low-risk’ patients is high if the risk is calculated accurately.
Insights presented in this article are an outcome of extensive market research by Future Market Insights and can be viewed in detail at here.